Next, we performed IGFBP2 IHC on matched tumor biopsies from five patients with BRAFV600E/K metastatic melanoma treated with dabrafenib + trametinib taken before treatment (Pre), early during treatment (EDT), and at disease progression (Prog)47 (Supplementary Data 5). This evidence concerns the gene IGFBP2 and neoplasm.